



## Suven Life Sciences Limited

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, Hyderabad, Telangana, India 500034  
CIN: L24110TG1989PLC009713 Tel: +91 40 2354 1142/ 1152 email: investorservices@suven.com website: www.suven.com

### STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2025

Rs. In Lakhs

Sl. No.	PARTICULARS	STANDALONE					
		For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
<b>1</b>	<b>Income</b>						
	Revenue from operations	280.87	91.92	160.99	559.46	518.88	665.58
	Other Income	276.59	377.78	156.93	713.27	953.51	1,072.59
	<b>Total income</b>	<b>557.46</b>	<b>469.70</b>	<b>317.92</b>	<b>1,272.73</b>	<b>1,472.39</b>	<b>1,738.17</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	626.84	607.65	486.58	1,832.05	1,475.88	2,082.49
	d) Finance costs	-	-	0.79	-	4.66	4.66
	e) Depreciation and amortisation expense	134.58	131.68	153.35	403.10	447.50	582.17
	f) R & D Expenses	590.96	877.32	826.49	1,987.05	2,194.43	3,043.16
	g) Other Expenses	552.25	397.56	177.90	1,420.08	550.89	733.67
	<b>Total expenses</b>	<b>1,904.63</b>	<b>2,014.21</b>	<b>1,645.11</b>	<b>5,642.28</b>	<b>4,673.36</b>	<b>6,446.15</b>
<b>3</b>	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>(1,347.17)</b>	<b>(1,544.51)</b>	<b>(1,327.19)</b>	<b>(4,369.55)</b>	<b>(3,200.97)</b>	<b>(4,707.98)</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit before Tax (3-4)</b>	<b>(1,347.17)</b>	<b>(1,544.51)</b>	<b>(1,327.19)</b>	<b>(4,369.55)</b>	<b>(3,200.97)</b>	<b>(4,707.98)</b>
<b>6</b>	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	-
<b>7</b>	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>(1,347.17)</b>	<b>(1,544.51)</b>	<b>(1,327.19)</b>	<b>(4,369.55)</b>	<b>(3,200.97)</b>	<b>(4,707.98)</b>
<b>8</b>	<b>Other Comprehensive Income</b>						
<b>8.a</b>	(i) Items that will not be reclassified to profit or loss	3.26	(1.50)	(0.45)	0.26	(1.35)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
<b>8.b</b>	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>3.26</b>	<b>(1.50)</b>	<b>(0.45)</b>	<b>0.26</b>	<b>(1.35)</b>	<b>(5.99)</b>
<b>9</b>	<b>Total Comprehensive Income for the period (7+8)</b>	<b>(1,343.91)</b>	<b>(1,546.01)</b>	<b>(1,327.64)</b>	<b>(4,369.29)</b>	<b>(3,202.32)</b>	<b>(4,713.97)</b>
<b>10</b>	Paid-up equity share capital	2,274.74	2,274.74	2,180.74	2,274.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
<b>11</b>	Other Equity						77,770.36
<b>12</b>	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>						
	a) Basic	(0.60)	(0.70)	(0.61)	(1.95)	(1.47)	(2.16)
	b) Diluted	(0.60)	(0.70)	(0.61)	(1.95)	(1.47)	(2.16)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



*U. S. J. S.*

		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
1	<b>Income</b>						
	Revenue from operations	280.87	91.92	160.99	559.46	518.88	665.58
	Other Income	277.45	377.80	163.05	715.23	967.44	1,089.69
	<b>Total income</b>	<b>558.32</b>	<b>469.72</b>	<b>324.04</b>	<b>1,274.69</b>	<b>1,486.32</b>	<b>1,755.27</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	626.84	607.65	486.58	1,832.05	1,475.88	2,082.49
	d) Finance costs	-	-	0.79	-	4.66	4.66
	e) Depreciation and amortisation expense	134.58	131.68	153.35	403.10	447.50	582.17
	f) R & D Expenses	9,404.72	7,032.13	3,413.32	20,585.69	10,663.68	14,396.18
	g) Other Expenses	584.36	429.25	181.66	1,528.71	574.61	764.27
	<b>Total expenses</b>	<b>10,750.50</b>	<b>8,200.71</b>	<b>4,235.70</b>	<b>24,349.55</b>	<b>13,166.33</b>	<b>17,829.77</b>
3	<b>Profit before exceptional items, Tax (1-2)</b>	<b>(10,192.18)</b>	<b>(7,730.99)</b>	<b>(3,911.66)</b>	<b>(23,074.86)</b>	<b>(11,680.01)</b>	<b>(16,074.50)</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit before Tax (3-4)</b>	<b>(10,192.18)</b>	<b>(7,730.99)</b>	<b>(3,911.66)</b>	<b>(23,074.86)</b>	<b>(11,680.01)</b>	<b>(16,074.50)</b>
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	-
7	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>(10,192.18)</b>	<b>(7,730.99)</b>	<b>(3,911.66)</b>	<b>(23,074.86)</b>	<b>(11,680.01)</b>	<b>(16,074.50)</b>
8	<b>Other Comprehensive Income</b>						
8.a	(i) Items that will not be reclassified to profit or loss	3.26	(1.50)	(0.45)	0.26	(1.35)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	(78.39)	10.02	-	(71.99)	-	(52.34)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(75.13)</b>	<b>8.52</b>	<b>(0.45)</b>	<b>(71.73)</b>	<b>(1.35)</b>	<b>(58.33)</b>
9	<b>Total Comprehensive Income for the period (7+ 8)</b>	<b>(10,267.31)</b>	<b>(7,722.47)</b>	<b>(3,912.11)</b>	<b>(23,146.59)</b>	<b>(11,681.36)</b>	<b>(16,132.83)</b>
10	Paid-up equity share capital	2,274.74	2,274.74	2,180.74	2,274.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	8,817.94
12	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>						
	a) Basic	(4.55)	(3.48)	(1.79)	(10.31)	(5.36)	(7.37)
	b) Diluted	(4.55)	(3.48)	(1.79)	(10.31)	(5.36)	(7.37)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



**NOTES:-**

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 29, 2026. The results for the quarter ended December 31, 2025 has been reviewed by our statutory auditors.
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the Wholly Owned Subsidiary, Suven Neurosciences, Inc.
- 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 5) ESOP: for the quarter ended December 31, 2025, the Company recognized an employee benefit expense (EBP) of Rs. 25.71 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of December 2025 amounts to Rs.79.44 lakhs.

During the II quarter, out of 2,21,800 options under the 1st tranche, 2,14,000 options were exercised, and the Company received ₹117.70 lakhs pursuant to the exercise of employee stock options under its ESOP scheme. As of the reporting date, the equity shares corresponding to these exercised options had been allotted on 24.07.2025. The remaining unexercised options under the 1st tranche continue to be available for exercise by eligible employees, as the vesting period extends until 06-May-2027.

- 6) Preferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025.

Each warrant is convertible into one equity share of face value ₹1/- at an exercise price of ₹134/- per share, within a period of 18 months from the date of allotment.

Out of the Issue proceeds of Rs.85,764 Lakhs, Rs.58,219 Lakhs has been received and Rs. 27,545 Lakhs is yet to be received from warrant holders. During the II quarter the Company has allotted 9186490 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants (allotted on 16.07.2025) to three allottees, upon receipt of 100% of the warrant consideration amounting to Rs.12,309.90 lakhs.

Summary of Utilisation of Proceeds of Preferential issue as on 31.12.2025

Particulars	Amount Rs.In lakhs
Amount Received through Preferential Issue	58,218.72
Less: Amount Utilised	18,062.24
<b>Balance Amount</b>	<b>40,156.48</b>

- 7) The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21, 2025. The corresponding supporting rules under these codes are yet to be notified. The Company is in the process of evaluating the full impact of these new labour codes.

The Company has recognised and accounted for incremental liability for employee benefit expenses of Rs.36.34 Lakhs with respect to gratuity which is not material to the financial results. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the New Labour Code.

- 8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.



For SUVEN LIFE SCIENCES LIMITED

*Venkata Jasti*

**VENKAT JASTI**  
Chairman & MD  
DIN: 00278028

Place: Hyderabad  
Date : January 29, 2026

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
UNAUDITED STANDALONE FINANCIAL RESULTS**

**To**  
**The Board of Directors of**  
**SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED** for the quarter and nine months ended December 31, 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended.
2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KARVY & CO**  
Chartered Accountants  
(Firm Registration No.001757S)



**AJAYKUMAR KOSARAJU**  
Partner  
M.No. 021989  
UDIN: 26021989GCMUCW7178

Place: Hyderabad  
Date : 29/01/2026



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS**

To  
**The Board of Directors of  
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation')

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

<b>Name of the Company</b>	<b>Relationship</b>
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary



29/01/2026

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflects total revenues of Rs. -Nil-, and Rs. -Nil- for the quarter ended and nine months period ended December 31, 2025 and total net loss after tax of Rs.(8,845.01) lakhs and Rs.(18,705.31) Lakhs for the quarter ended and nine months period ended December 31, 2025, and total comprehensive income of Rs.(8,923.40) Lakhs and Rs.(18,777.30) Lakhs for the quarter ended and nine months period December 31, 2025 as considered in the Statement. This interim financial information has been reviewed by another auditor whose report has been furnished to us by the Management, and our conclusion on the Statement, insofar as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

**For KARVY & CO.,**  
Chartered Accountants  
(Firm Registration No .001757S)



**AJAYKUMAR KOSARAJU**  
Partner  
M.No.021989  
UDIN:26021989YABYXS4255



Place: Hyderabad  
Date : 29/01/2026

29/01/2026